Localized, borderline resectable and metastatic gastrointestinal stromal tumors (GISTs)

Authored by Michael Wagner, published on 2026-05-28 00:56:16.0

This algorithm is broadly aligned with contemporary GIST management: upfront histologic diagnosis, mandatory KIT/PDGFRA molecular testing to guide systemic therapy, risk-adapted use of adjuvant imatinib after complete resection, and standard TKI sequencing for advanced disease (imatinib → sunitinib → regorafenib → ripretinib) with avapritinib for PDGFRA D842V. Neoadjuvant imatinib for borderline resectable disease with sensitive mutations and response-based timing of surgery is consistent with major guidelines, though evidence is largely nonrandomized. Surveillance intervals are generally consistent with guideline ranges but vary across societies and are often individualized.

GASTROINTESTINAL STROMAL TUMORS (GISTs) TREATMENT DIAGNOSIS

Histologic confirmation of GIST
- MUTATION TESTING
  
  KIT and PDGFRA mutation testing (required before systemic therapy). Frequency: ~80% KIT ~10% PDGFRA ~10% Wild-type / rare molecular subtype (SDH-deficient GIST, BRAF V600E, NF1-associated GIST, NTRK fusion-positive, RAS pathway mutations, FGFR alterations and PIK3CA mutations)
  - STAGING
    
    Assess extent of disease (CT/MRI ± PET as indicated)
    - MULTIDISCIPLINARY REVIEW
      
      Surgical oncology, medical oncology, radiology, pathology
      - LOCALIZED RESECTABLE
        
        (No metastasis)
        
        SURGERY
        
        Complete surgical resection with negative margins (avoid tumor rupture)
        
        RISK ASSESSMENT
        
        Tumor size; Mitotic rate; Tumor location; Tumor rupture (if present, treat as very high risk)
        
        LOW / VERY LOW RISK
        
        Surveillance (No adjuvant therapy)
        
        SURVEILLANCE AFTER SURGERY
        
        CT or MRI of abdomen/pelvis • Very low / low risk: every 6–12 months for 5 years, then annually • Intermediate / high risk: every 3–6 months for 3–5 years, then every 6–12 months (Adjust based on risk and clinical judgment)
        
        INTERMEDIATE RISK
        
        Individualized consideration of adjuvant imatinib vs. surveillance
        
        SURVEILLANCE AFTER SURGERY
        
        CT or MRI of abdomen/pelvis • Very low / low risk: every 6–12 months for 5 years, then annually • Intermediate / high risk: every 3–6 months for 3–5 years, then every 6–12 months (Adjust based on risk and clinical judgment)
        
        HIGH / VERY HIGH RISK
        
        Adjuvant imatinib (typically 3 years)
        
        SURVEILLANCE AFTER SURGERY
        
        CT or MRI of abdomen/pelvis • Very low / low risk: every 6–12 months for 5 years, then annually • Intermediate / high risk: every 3–6 months for 3–5 years, then every 6–12 months (Adjust based on risk and clinical judgment)
      - BORDERLINE RESECTABLE / LOCALLY ADVANCED
        
        (High morbidity surgery anticipated or marginally resectable)
        
        NEOADJUVANT IMATINIB
        
        For tumors with sensitive KIT or PDGFRA mutations (not for PDGFRA D842V) Assess response every 2–3 months (CT/MRI)
        
        SURGERY
        
        Resection after maximal safe response
        
        RISK ASSESSMENT
        
        Same factors as in A2 (Include tumor rupture)
        
        LOW / INTERMEDIATE RISK
        
        Surveillance or consider adjuvant imatinib
        
        SURVEILLANCE AFTER SURGERY
        
        CT or MRI of abdomen/pelvis • Very low / low risk: every 6–12 months for 5 years, then annually • Intermediate / high risk: every 3–6 months for 3–5 years, then every 6–12 months (Adjust based on risk and clinical judgment)
        
        HIGH / VERY HIGH RISK
        
        Adjuvant imatinib (typically 3 years)
        
        SURVEILLANCE AFTER SURGERY
        
        CT or MRI of abdomen/pelvis • Very low / low risk: every 6–12 months for 5 years, then annually • Intermediate / high risk: every 3–6 months for 3–5 years, then every 6–12 months (Adjust based on risk and clinical judgment)
      - METASTATIC / UNRESECTABLE DISEASE
        
        MUTATION-DIRECTED INITIAL THERAPY
        
        PDGFRA EXON 18 D842V MUTATION
        
        Avapritinib (first-line preferred)
        
        MANAGEMENT AT PROGRESSION
        
        Confirm progression radiographically; Assess adherence and drug interactions; Consider dose escalation of imatinib (e.g., KIT exon 9 or suboptimal exposure); Re-biopsy / mutation analysis if feasible
        
        SECOND-LINE THERAPY
        
        Sunitinib
        
        THIRD-LINE THERAPY
        
        Regorafenib
        
        FOURTH-LINE THERAPY
        
        Ripretinib
        
        CLINICAL TRIALS
        
        Consider at any line of therapy
        
        OTHER KIT / PDGFRA MUTATIONS (imatinib-sensitive)
        
        Imatinib (first-line)
        
        MANAGEMENT AT PROGRESSION
        
        Confirm progression radiographically; Assess adherence and drug interactions; Consider dose escalation of imatinib (e.g., KIT exon 9 or suboptimal exposure); Re-biopsy / mutation analysis if feasible
        
        SECOND-LINE THERAPY
        
        Sunitinib
        
        THIRD-LINE THERAPY
        
        Regorafenib
        
        FOURTH-LINE THERAPY
        
        Ripretinib
        
        CLINICAL TRIALS
        
        Consider at any line of therapy
Multidisciplinary evaluation at a high-volume sarcoma center is recommended for all patients with sarcoma

tos privacy